UNSPSC 51141522: Oxcarbazepine

This classification denotes an anticonvulsant agent with the molecular formula C15H12N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VZI5B1W380, chemically known as 10,11-dihydro-10-oxo-5h-dibenz(b,f)azepine-5-carboxamide but generally known as oxcarbazepine, which bears US NIH Compound Identifier 34312. European Medicines Agency schedules Oxcarbazepine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09510MIG.

UNSPSC 51141522 Oxcarbazepine is a Commodity code nominally for a specific anticonvulsant medication, but the recent state and local opportunities tagged under it reflect broader pharmaceutical procurement activity across health agencies, pharmacy benefit programs, and cooperative purchasing alliances rather than single-drug sourcing. State and local governments use this code pathway to solicit generic pharmaceuticals, over-the-counter products, naloxone and drug-deactivation systems, and direct-to-manufacturer prescription programs. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances administering contracts on behalf of multiple member jurisdictions. The scope ranges from discrete emergency-response medications (naloxone) to comprehensive generic pharmaceutical catalogs with hundreds of products delivered through established wholesale channels, reflecting procurement patterns where jurisdictions consolidate pharmaceutical sourcing under shared cooperative agreements rather than individual commodity codes.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 (due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug-deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, seeking information on direct contracting models outside traditional pharmacy benefit managers and wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026 and contract terms of two years for new vendors with optional extensions. All three solicitations emphasize compliance with federal and state pharmaceutical regulations, E-Verify requirements, and substantial insurance coverage mandates.